Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
about
Finding specific 10-joint Juvenile Arthritis Disease Activity Score (JADAS10) and clinical JADAS10 cut-off values for disease activity levels in non-systemic juvenile idiopathic arthritis: a Finnish multicentre studyTreatment of juvenile idiopathic arthritis: a revolution in carePrediction of methotrexate efficacy and adverse events in patients with juvenile idiopathic arthritis: a systematic literature reviewAdvances in the treatment of polyarticular juvenile idiopathic arthritisJuvenile Idiopathic Arthritis: Diagnosis and TreatmentWhat are the immunological consequences of long-term use of biological therapies for juvenile idiopathic arthritis?Polyarticular juvenile idiopathic arthritis - epidemiology and management approachesChildhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritisTrial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.Patient-reported Outcomes across Categories of Juvenile Idiopathic ArthritisContrast-enhanced MRI of the knee in children unaffected by clinical arthritis compared to clinically active juvenile idiopathic arthritis patients.Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept CohortMethotrexate efficacy, but not its intolerance, is associated with the dose and route of administrationUpdate on the treatment of juvenile idiopathic arthritisAttainment of inactive disease status following initiation of TNF-α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active diseaseAssessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists.Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-α inhibitors: systematic review of the literature.Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use.A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.JIA in 2011: New takes on categorization and treatment.The clinical spectrum of juvenile idiopathic arthritis in a large urban population.Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Importance of adherence in the outcome of juvenile idiopathic arthritis.Methotrexate in juvenile idiopathic arthritis: towards tailor-made treatment.Judicious use of biologicals in juvenile idiopathic arthritis.Safety of biologic therapies for the treatment of juvenile idiopathic arthritis.Novel treatment options for juvenile idiopathic arthritis.Biologic-associated infections in pediatric rheumatology.The role of synthetic drugs in the biologic era: therapeutic strategies for treating juvenile idiopathic arthritis.Recent advances in the use of Anti-TNFα therapy for the treatment of juvenile idiopathic arthritis.Difficult-To-Treat Juvenile Idiopathic Arthritis: Current and Future Options.Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis.How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition.Understanding inflammation in juvenile idiopathic arthritis: How immune biomarkers guide clinical strategies in the systemic onset subtype.Cost of biologics in the treatment of juvenile idiopathic arthritis: a factor not to be overlooked.Biologics in juvenile idiopathic arthritis: a narrative review.Occurrence of adverse events in patients with JIA receiving biologic agents: long-term follow-up in a real-life setting.Diagnosis and treatment of enthesitis-related arthritis.
P2860
Q26786198-7CAC810A-2183-4E81-B564-A5C09621DAE1Q26849497-1B876C2B-4468-491A-AF14-9CB2C7CF4498Q26991741-35E1A1E8-701E-4382-88BE-6DEFC516A566Q27001017-0DA073FF-6C17-44EF-98C8-E5A7AED1E21CQ28079246-3B5D70A0-851B-4469-B091-B71F0DDCEBABQ33765738-F1B49256-B47D-41C7-A1E4-9D81273A7F51Q34434750-3D23600F-F06E-47A1-8349-AF49C72FC323Q35743755-06487931-188D-4653-AB9C-8D55218957F9Q35870808-E5AF0C7A-1AF0-48CB-B168-0F5D4147E1C1Q36118097-66979912-80C2-4A34-9998-B8DEC158F765Q36651293-D641FEF6-0A3E-41AF-8FC1-93697D839589Q36795982-08CB3F7E-B6A1-4228-B23A-47449F8192CAQ37006464-0B5E436A-9FE8-4081-8C97-84769E38FCE4Q37060351-94973C4A-E2E5-4AA8-BBBD-69344CAA2E69Q37133996-A2768366-C2DB-4941-BF21-A70796137147Q37428914-53E15209-D1E7-4D6E-8BEC-507F93291B29Q37436386-B37E24FF-F603-4007-AE23-1ED40AB2758FQ37463702-26661798-4F45-4F0E-90E9-EAA8DCB9881DQ37618733-2FFDD040-CB21-4776-A480-A42857FFBEAEQ37627929-51265BA1-7805-4E54-9A25-9FD0C6EA614FQ37974498-17A23127-1184-4691-9361-D2E098505E53Q37981131-8B4D61CF-3055-42A9-AC50-03E0579D5AAFQ38061615-BCB9FD6C-2219-47C9-A3B6-ADCE32481B97Q38092899-102A2424-C27F-4E9A-85C2-96FB43230A9FQ38185951-8463FC53-9AF5-438A-AE2C-E8B29404F2F7Q38214382-6838FBE3-E9C7-4D7F-A323-95B01EBD12D0Q38248905-9A267B08-287E-4446-B4DB-DD2BB7998D45Q38530469-2F1C6FC0-CBB5-4982-9CA5-81C40108BE54Q38570721-5DB2F0A1-8542-4FA3-8AD9-F33DD2E597ADQ38589392-2DBCC501-F939-4912-8A6D-369453A03C65Q38672339-9FD95925-838A-49C2-97F4-1D5DFF523443Q38711172-51A6988D-45CF-4384-B2EB-A8AF7AD4408DQ38759376-3396C2AC-C362-4307-A161-B864359F43AEQ38805990-2FFA36D9-F165-47EC-83FA-E44D64F13C76Q38847169-835ADDA2-92A5-4DDF-ACD8-B018F469AADBQ38909520-F270F50C-1148-43E3-ADAB-194A7BEAE7D5Q39432090-6822F201-DB9E-4917-9436-B674FE929785Q39446782-EE02F85A-A5EF-4A18-B22F-6A210811D0B6Q41600541-3C3A0D14-439C-41A3-8067-B799392F3826Q41858221-5347FC99-03BC-4F03-94DE-812BB0815D85
P2860
Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Aggressive combination drug th ...... sed open-label clinical trial.
@en
type
label
Aggressive combination drug th ...... sed open-label clinical trial.
@en
prefLabel
Aggressive combination drug th ...... sed open-label clinical trial.
@en
P2093
P356
P1476
Aggressive combination drug th ...... sed open-label clinical trial.
@en
P2093
Anne Putto-Laurila
Kristiina Aalto
Liisa Kröger
Maarit Tarkiainen
Merja Malin
Paula Vähäsalo
Pekka Lahdenne
Pirjo Tynjälä
Visa Honkanen
P304
P356
10.1136/ARD.2010.143347
P407
P577
2011-05-28T00:00:00Z